Xbrane Biopharma AB (publ) reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was SEK 57.62 million compared to SEK 10.71 million a year ago. Net loss was SEK 172.51 million compared to SEK 188.38 million a year ago.

Basic loss per share from continuing operations was SEK 6.59 compared to SEK 7.77 a year ago. Diluted loss per share from continuing operations was SEK 6.59 compared to SEK 7.77 a year ago. Basic loss per share was SEK 6.75 compared to SEK 7.98 a year ago.

Diluted loss per share was SEK 6.75 compared to SEK 7.98 a year ago.